Background: We sought to quantify temporal patterns in baseline risk, treatment, and outcomes of non-ST elevation acute coronary syndrome (NSTE ACS) patients enrolled in randomized clinical trials (RCT) over a 15-year period using available databases from 7 major multinational RCTs of glycoprotein IIb/IIIa inhibition in NSTE ACS.
Methods:
The study population comprised 40,782 patients enrolled from 1994-2008 in PURSUIT, PRISM, PRISM-PLUS, PARAGON A, PARAGON B, GUSTO IV-ACS, and EARLY ACS. Patient characteristics, co-therapies, and outcomes were temporally mapped to 4 time domains describing time periods of randomization. Tests of statistical trend were performed using randomization month as a continuous variable.
Results:
Over time, patient age increased, and patients were more likely to have diabetes, prior heart failure, and positive cardiac markers at randomization, but less often had prior myocardial infarction (Table) . Use of thienopyridines, statins, angiotensin-converting enzyme inhibitors, and beta-blockers increased markedly. Composite death or myocardial infarction rates decreased, but mortality remained unchanged.
Conclusion:
Despite enrollment of patients with substantially higher risk profiles into these RCTs of NSTE ACS, with concurrent increases in the use of evidence-based co-therapies, short-term mortality risk has remained constant over the past 15 years. These data add insight into future trends in the clinical substrate and specific outcomes driving RCTs. 
